Development, clinical translation, and utility of a COVID-19 antibody test with qualitative and quantitative readouts
Abstract The COVID-19 global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to place an immense burden on societies and healthcare systems. A key component of COVID-19 control efforts is serologic testing to determine the community prevalence of SARS-CoV-2 exposure and quantify individual immune responses to prior infection or vaccination. Here, we describe a laboratory-developed antibody test that uses readily available research-grade reagents to detect SARS-CoV-2 exposure in patient blood samples with high sensitivity and specificity. We further show that this test affords the estimation of viral spike-specific IgG titers from a single sample measurement, thereby providing a simple and scalable method to measure the strength of an individual’s immune response. The accuracy, adaptability, and cost-effectiveness of this test makes it an excellent option for clinical deployment in the ongoing COVID-19 pandemic..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.09.10.20192187 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018734154 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018734154 | ||
| 003 | DE-627 | ||
| 005 | 20240425104736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200914s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.09.10.20192187 |2 doi | |
| 035 | |a (DE-627)XBI018734154 | ||
| 035 | |a (biorXiv)10.1101/2020.09.10.20192187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bortz, Robert H. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development, clinical translation, and utility of a COVID-19 antibody test with qualitative and quantitative readouts |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The COVID-19 global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to place an immense burden on societies and healthcare systems. A key component of COVID-19 control efforts is serologic testing to determine the community prevalence of SARS-CoV-2 exposure and quantify individual immune responses to prior infection or vaccination. Here, we describe a laboratory-developed antibody test that uses readily available research-grade reagents to detect SARS-CoV-2 exposure in patient blood samples with high sensitivity and specificity. We further show that this test affords the estimation of viral spike-specific IgG titers from a single sample measurement, thereby providing a simple and scalable method to measure the strength of an individual’s immune response. The accuracy, adaptability, and cost-effectiveness of this test makes it an excellent option for clinical deployment in the ongoing COVID-19 pandemic. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Florez, Catalina |e verfasserin |4 aut | |
| 700 | 1 | |a Laudermilch, Ethan |e verfasserin |4 aut | |
| 700 | 1 | |a Wirchnianski, Ariel S. |e verfasserin |4 aut | |
| 700 | 1 | |a Lasso, Gorka |e verfasserin |4 aut | |
| 700 | 1 | |a Malonis, Ryan J. |e verfasserin |4 aut | |
| 700 | 1 | |a Georgiev, George I. |e verfasserin |4 aut | |
| 700 | 1 | |a Vergnolle, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera, Natalia G. |e verfasserin |4 aut | |
| 700 | 1 | |a Morano, Nicholas C. |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Sean T. |e verfasserin |4 aut | |
| 700 | 1 | |a Orner, Erika P. |e verfasserin |4 aut | |
| 700 | 1 | |a Mengotto, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Dieterle, M. Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Fels, J. Maximilian |e verfasserin |4 aut | |
| 700 | 1 | |a Haslwanter, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Jangra, Rohit K. |e verfasserin |4 aut | |
| 700 | 1 | |a Celikgil, Alev |e verfasserin |4 aut | |
| 700 | 1 | |a Kimmel, Duncan |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, James H. |e verfasserin |4 aut | |
| 700 | 1 | |a Mariano, Margarette |e verfasserin |4 aut | |
| 700 | 1 | |a Nakouzi, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Quiroz, Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Szymczak, Wendy A. |e verfasserin |0 (orcid)0000-0002-0747-1169 |4 aut | |
| 700 | 1 | |a Tong, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Barnhill, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Forsell, Mattias N. E. |e verfasserin |0 (orcid)0000-0001-6904-742X |4 aut | |
| 700 | 1 | |a Ahlm, Clas |e verfasserin |4 aut | |
| 700 | 1 | |a Stein, Daniel T. |e verfasserin |4 aut | |
| 700 | 1 | |a Pirofski, Liise-anne |e verfasserin |4 aut | |
| 700 | 1 | |a Goldstein, D. Yitzchak |e verfasserin |4 aut | |
| 700 | 1 | |a Garforth, Scott J. |e verfasserin |4 aut | |
| 700 | 1 | |a Almo, Steven C. |e verfasserin |4 aut | |
| 700 | 1 | |a Daily, Johanna P. |e verfasserin |4 aut | |
| 700 | 1 | |a Prystowsky, Michael B. |e verfasserin |4 aut | |
| 700 | 1 | |a Faix, James D. |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Amy S. |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Louis M. |e verfasserin |0 (orcid)0000-0002-0357-7396 |4 aut | |
| 700 | 1 | |a Lai, Jonathan R. |e verfasserin |4 aut | |
| 700 | 1 | |a Chandran, Kartik |e verfasserin |0 (orcid)0000-0003-0232-7077 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1128/msphere.00224-21 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.09.10.20192187 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||